TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15657588

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy at diagnosis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed parathyroidectomy (1 year later)
Number of subjects: 50
Study: 11710858

Group type: EXPERIMENTAL
Intervention: Unilateral autologous platelet-rich plasma wound treatment (APG) during standard deep-plane rhytidectomy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Non-APG-treated side
Number of subjects: 8
Study: 9475316

Group type: EXPERIMENTAL
Intervention: Neonatal respiratory distress syndrome group
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 9
Study: 2884858

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28821365

Group type: EXPERIMENTAL
Intervention: Morphine 0.1mg/kg and ketamine 0.15mg/kg (MK group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Morphine 0.1mg/kg and placebo (MP group)
Number of subjects: 106
Study: 27256093

Group type: EXPERIMENTAL
Intervention: Sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Combination CapeOX/mFOLFOX6-Bmab
Number of subjects: 304
Study: 25540041

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (four weekly 30-minute calls and written resources)
Number of subjects: 394
Study: 22810395

Group type: EXPERIMENTAL
Intervention: Single-row fixation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Double-row fixation
Number of subjects: 90
Study: 20585226

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis using linear and generalized linear mixed models
Number of subjects: 0
Study: 18776782

Group type: EXPERIMENTAL
Intervention: Percutaneous release of the A1 pulley using a #15 blade
Number of subjects: 36

Group type: COMPARATOR
Intervention: Open release of the A1 pulley
Number of subjects: 36
Study: 16837721

Group type: EXPERIMENTAL
Intervention: artemether‐lumefantrine (Coartem)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (ASAQ)
Number of subjects: 137
Study: 14554218

Group type: EXPERIMENTAL
Intervention: etanercept (25 mg s.q., twice/week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 10927727

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 82

Group type: COMPARATOR
Intervention: Needle-insertion control
Number of subjects: 82

Group type: COMPARATOR
Intervention: No-needle relaxation control
Number of subjects: 82
Study: 8881340

Group type: EXPERIMENTAL
Intervention: High-preference stimuli
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Middle-preference stimuli
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Low-preference stimuli
Number of subjects: 4
Study: 1555624

Group type: EXPERIMENTAL
Intervention: L-propionylcarnitine 600 mg i.v. single bolus
Number of subjects: 33

Group type: COMPARATOR
Intervention: L-carnitine 500 mg i.v. equimolar dose
Number of subjects: 33

Group type: COMPARATOR
Intervention: L-propionylcarnitine and L-carnitine
Number of subjects: 33
Study: 2934779

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.2 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30371302

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 96
Study: 27908164

Group type: EXPERIMENTAL
Intervention: SAFIRE (sinogram affirmed iterative reconstruction)
Number of subjects: 23

Group type: COMPARATOR
Intervention: FBP (filtered‐backprojection)
Number of subjects: 23
Study: 24652109

Group type: EXPERIMENTAL
Intervention: Unsedated techniques (VCE and uTNE)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Information on Barrett's esophagus (BE)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: History of undergoing screening tests and GI symptoms
Number of subjects: 136
Study: 22403352

Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass
Number of subjects: 33
Study: 20157671

Group type: EXPERIMENTAL
Intervention: Experimental primers with RRP fillers (various combinations of MPS, BMEP, and EGMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial etch-and-rinse adhesive (control)
Number of subjects: 0
Study: 18576902

Group type: EXPERIMENTAL
Intervention: Intranasal haloperidol 2.5 mg (2.5 mg/0.1‐ml spray into a single naris)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intravenous haloperidol 2.5 mg (0.5 ml of 5.0 mg/ml) infused over 15 minutes
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intramuscular haloperidol 2.5 mg (0.5 ml of 5.0 mg/ml)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intranasal haloperidol 2.5 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intranasal haloperidol
Number of subjects: 4
Study: 16278497

Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel) in phase IV community cohort study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept (Enbrel) in phase III RCTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: RCT patients
Number of subjects: 0
Study: 12425705

Group type: EXPERIMENTAL
Intervention: GH + HRT
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: GH + testosterone
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 131
Study: 10420094

Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1 mg/day over 6 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Desacetyl‐α‐MSH (1.68 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Desacetyl‐α‐MSH (subchronic treatment)
Number of subjects: 54
Study: 8937121

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg, p.o., qam, daily for 6 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg, p.o., qam, daily for 6 weeks) plus Amoxicillin (1500 mg, p.o, t.i.d., daily for 2 weeks)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lansoprazole and Amoxicillin combination
Number of subjects: 63
Study: 1877125

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (Gore‐Tex) sutures
Number of subjects: 24

Group type: COMPARATOR
Intervention: Polypropylene (Prolene) sutures
Number of subjects: 24
Study: 7049204

Group type: EXPERIMENTAL
Intervention: Oral mexiletine
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 31243156

Group type: EXPERIMENTAL
Intervention: Population health intervention involving a clinical pharmacist reviewing charts and contacting primary care providers for anticoagulation management.
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 432
Study: 30277547

Group type: EXPERIMENTAL
Intervention: Empathy frame
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Patient management frame
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control frame
Number of subjects: 183
Study: 27571387

Group type: EXPERIMENTAL
Intervention: New participatory, supportive return-to-work program
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 24820727

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Nasal endotracheal intubation (ET)
Number of subjects: 171
Study: 22286364

Group type: COMPARATOR
Intervention: Calcium-modified orange juice (1.6 g/l of calcium) (C+)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orange juice with 0.4 g/l of calcium from calcium lactate pentahydrate (Ca)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Orange juice with 0.2 g/l of linear sodium polyphosphate (LPP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of calcium and LPP (Ca+LPP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Commercially available orange juice (negative control, C-)
Number of subjects: 10
Study: 20133491

Group type: EXPERIMENTAL
Intervention: Tenecteplase (2 mg)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 17377905

Group type: EXPERIMENTAL
Intervention: 3F-CVVH (high-adsorption hemofiltration)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1F-CVVH (standard hemofiltration)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control blood (1F-CVVH)
Number of subjects: 12
Study: 15327134

Group type: EXPERIMENTAL
Intervention: Selective alpha1A/D-adrenoblocker tamsulosin
Number of subjects: 0
Study: 11593093

Group type: EXPERIMENTAL
Intervention: Weight loss (10%) in obese hypertensive subjects
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Weight loss maintenance period
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dietary fatty acid intervention
Number of subjects: 52
Study: 9850939

Group type: EXPERIMENTAL
Intervention: Idebenone 90 mg tid for 24 months
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Idebenone 120 mg tid for 24 months
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo for 12 months followed by idebenone 90 mg tid for another 12 months
Number of subjects: 450
Study: 7989621

Group type: EXPERIMENTAL
Intervention: SofScale pre-scaling gel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 31
Study: 3059235

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 20
Study: 30830672

Group type: EXPERIMENTAL
Intervention: Anodal ctDCS (2.0 mA, 20 min per day, 5 days a week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham ctDCS
Number of subjects: 14
Study: 28426678

Group type: EXPERIMENTAL
Intervention: Nutrition education combined with food security activities
Number of subjects: 24

Group type: COMPARATOR
Intervention: Food security activities only (Control)
Number of subjects: 24
Study: 26216472

Group type: EXPERIMENTAL
Intervention: Simple-to-complex training protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous training protocol
Number of subjects: 0
Study: 23929580

Group type: EXPERIMENTAL
Intervention: Communication skills course
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no communication skills course)
Number of subjects: 60
Study: 21726464

Group type: EXPERIMENTAL
Intervention: Risk factors associated with microalbuminuria
Number of subjects: 886
Study: 19332211

Group type: EXPERIMENTAL
Intervention: Universal beta-blockade (UBB; n = 197) comprising an algorithm‐based, nurse‐led strategy to optimize dosing and adherence to bisoprolol titration over > or =1 week preoperatively
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care (UC; n = 203) whereby beta-blockers are continued in those already taking them or prescribed for patients identified as high risk based on ischemia
Number of subjects: 400
Study: 15764956

Group type: EXPERIMENTAL
Intervention: Nutrition with 10 mg of OX administered orally twice a day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nutrition with progressive resistance training (PRT) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nutrition alone (NA) with placebo pills
Number of subjects: 50
Study: 10486791

Group type: EXPERIMENTAL
Intervention: Combined esterified estrogen-methyltestosterone therapy (0.625 mg esterified estrogen + 1.25 mg methyltestosterone or 1.25 mg esterified estrogen + 2.5 mg methyltestosterone)
Number of subjects: 641

Group type: COMPARATOR
Intervention: Estrogen therapy alone
Number of subjects: 641
Study: 7493415

Group type: EXPERIMENTAL
Intervention: High-dose phentolamine (0.3 +/- 0.1 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Medium-dose phentolamine (0.2 +/- 0.0 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose phentolamine (0.1 +/- 0.0 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-dose phentolamine (0.6 +/- 1 degrees C)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All doses of phentolamine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Medium and high doses of phentolamine
Number of subjects: 10
Study: 1903846

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine consisting of H. influenzae type b polysaccharide and Neisseria meningitidis OMPC
Number of subjects: 5188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5188

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 5188
Study: 6263476

Group type: EXPERIMENTAL
Intervention: HAM (hexamethylmelamine, doxorubicin, and methotrexate)
Number of subjects: 284

Group type: COMPARATOR
Intervention: C (cyclophosphamide and CCNU)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Crossover therapy with VM‐26 or ascorbic acid
Number of subjects: 284
Study: 30794296

Group type: EXPERIMENTAL
Intervention: Physical therapy exercise (n=96)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Community-based group exercise (n=96)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (control arm, n=48)
Number of subjects: 240
Study: 29581079

Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing therapy (thiazolidinediones)
Number of subjects: 2319

Group type: COMPARATOR
Intervention: Insulin-providing therapy (insulin, sulfonylurea, or a meglitinide)
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (while exposed)
Number of subjects: 2319

Group type: COMPARATOR
Intervention: No exposure to thiazolidinediones
Number of subjects: 2319

Group type: EXPERIMENTAL
Intervention: Subset of patients matched on propensity to receive thiazolidinediones
Number of subjects: 2319
Study: 27179166

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation with lifestyle modification
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with lifestyle modification
Number of subjects: 50
Study: 24188510

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 116
Study: 21992111

Group type: EXPERIMENTAL
Intervention: Galantamine fast titration (8 mg/week increments to 16-24 mg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Galantamine slow titration (8 mg/4 weeks to 16-24 mg)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Galantamine (both titration arms)
Number of subjects: 89
Study: 20661022

Group type: EXPERIMENTAL
Intervention: Blonanserin
Number of subjects: 206

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 206
Study: 17156148

Group type: EXPERIMENTAL
Intervention: Bolus injection of 6-methyl-prednisolone (1 mg/kg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 6-methyl-prednisolone (1 mg/kg/day)
Number of subjects: 66
Study: 16301269

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EF; 15 mL of 1% ropivacaine plus 100 mug fentanyl)
Number of subjects: 45

Group type: COMPARATOR
Intervention: IV fentanyl (IF; 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 100 mug fentanyl)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (C; 15 mL of 1% ropivacaine plus 2 mL of normal saline followed by IV injection of 2 mL of normal saline)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (EF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: IV fentanyl (IF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 45
Study: 12184473

Group type: EXPERIMENTAL
Intervention: Available therapies for endometriosis
Number of subjects: 0
Study: 9661568

Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8704435

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 62
Study: 2717292

Group type: EXPERIMENTAL
Intervention: Liquid-crystal thermometer
Number of subjects: 503

Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Both groups (thermometer and pamphlet)
Number of subjects: 503
Study: 30955910

Group type: EXPERIMENTAL
Intervention: Massage (30-minute session)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no massage, only Sorenson test)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 36
Study: 27916314

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided breast-conserving surgery (USS)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Palpation-guided surgery (PGS)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: USS
Number of subjects: 134

Group type: COMPARATOR
Intervention: PGS
Number of subjects: 134
Study: 25839348

Group type: EXPERIMENTAL
Intervention: 3% diquafosol ophthalmic solution with high-WC CL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline with high-WC CL
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3% diquafosol ophthalmic solution with low-WC CL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline with low-WC CL
Number of subjects: 20

Group type: COMPARATOR
Intervention: High-WC CL wear
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-WC CL wear
Number of subjects: 20
Study: 23643154

Group type: EXPERIMENTAL
Intervention: Group family planning counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual family planning counseling
Number of subjects: 0
Study: 21537155

Group type: EXPERIMENTAL
Intervention: Octreotide 25 μg/hr
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Octreotide 50 μg/hr
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 19619203

Group type: EXPERIMENTAL
Intervention: Postdischarge transitional care programme (predischarge assessment, structured home visits, telephone follow-ups within four weeks after discharge)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Postdischarge transitional care programme
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 200
Study: 17464158

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-acupuncture waiting list condition
Number of subjects: 12
Study: 16226163

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg
Number of subjects: 1825

Group type: COMPARATOR
Intervention: Pravastatin, 40 mg
Number of subjects: 1825
Study: 12461368

Group type: EXPERIMENTAL
Intervention: Alumina-on-alumina ceramic bearing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cobalt chrome-on-polyethylene bearing
Number of subjects: 0
Study: 9861125

Group type: COMPARATOR
Intervention: Droperidol 1.25 mg bolus at induction followed by droperidol 0.1 mg per 1 mg of morphine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg bolus at induction followed by ondansetron 0.32 mg per 1 mg of morphine
Number of subjects: 60
Study: 7652039

Group type: EXPERIMENTAL
Intervention: Bright white light treatment (2500-3000 1x)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dim red light treatment (> 500 1x)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Night-shift work
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Full-spectrum white light treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dim red light treatment
Number of subjects: 14
Study: 2668253

Group type: EXPERIMENTAL
Intervention: Norfloxacin (200 mg) and amphotericin B (500 mg), twice daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 782701

Group type: EXPERIMENTAL
Intervention: BCNU plus adriamycin
Number of subjects: 13
Study: 31028508

Group type: EXPERIMENTAL
Intervention: It's Your Game...Keep It Real! (IYG) intervention
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Usual care (comparison condition)
Number of subjects: 1543
Study: 29392071

Group type: EXPERIMENTAL
Intervention: Intranasal splint with airway
Number of subjects: 60

Group type: COMPARATOR
Intervention: Merocel nasal packing
Number of subjects: 60
Study: 27136909

Group type: EXPERIMENTAL
Intervention: Trametinib pediatric oral solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablet formulation of trametinib
Number of subjects: 0
Study: 22561972

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg(‐1) of body weight, administered 60 minutes before exercise)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 21862954

Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 813

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study: 19099919

Group type: EXPERIMENTAL
Intervention: Pulmonary thromboendarterectomy (PTE) therapy (Group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conservative therapy (Group B)
Number of subjects: 63
Study: 17299195

Group type: EXPERIMENTAL
Intervention: Iron-reduction group (n = 636)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control group (n = 641)
Number of subjects: 1277
Study: 15082480

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg every other week
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg weekly
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 11330365

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 6 days
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg b.i.d. for 14 days
Number of subjects: 151

Group type: COMPARATOR
Intervention: Azithromycin 1.0 g single dose
Number of subjects: 151

Group type: COMPARATOR
Intervention: Doxycycline 100 mg b.i.d. for 7 days
Number of subjects: 151
Study: 8989017

Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Glycopyrrolate 8 micrograms/kg
Number of subjects: 14
Study: 8432669

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no OMT)
Number of subjects: 12